NO ROOM AT THE INN!
@HiltonHotels has launched a coordinated campaign in Minneapolis to REFUSE service to DHS law enforcement.
When officers attempted to book rooms using official government emails and rates, Hilton Hotels maliciously CANCELLED their reservations.
This is UNACCEPTABLE. Why is Hilton Hotels siding with murderers and rapists to deliberately undermine and impede DHS law enforcement from their mission to enforce our nation’s immigration laws?
🚨#BREAKING: I have obtained voting records of Asheville NC's Vice Mayor, Antanette Mosley...
...and she appears to have cast ballots in BOTH Georgia and North Carolina in 2008, 2012, and 2014.
Furthermore, it appears she also claimed a "homestead tax exemption" in Georgia which is legally only available to those with a permanent residence.
"No Kings" says the party of elderly tyrants who censored dissenters, tried to force mask/vax the entire country and got rich in office.
Chuck Schumer
Bernie Sanders
Nancy Pelosi
Ron Wyden
Ed Markey
Average age: 80.06 yrs
Avg time in office: 42.34 yrs
Avg net worth: $52,860,000
$ATOS announces key progress in its global intellectual-property strategy for Z-endoxifen, including the issuance of an Israeli patent and continued renewals that reinforce protection for the Company's lead program across major jurisdictions.
Read more: https://t.co/9ftSWALBYK
Yale confirms the future of #Cancer care:
Adaptive treatment for metastatic #BreastCancer as tumors evolve.
$ATOS is aligned.
Our (Z)-endoxifen program targets this paradigm, designed to remain effective as tumor profiles shift.
Platform-ready. Market-aware.
https://t.co/VxAIEcjvIZ
📢 Atossa Therapeutics $ATOS: Advancing a Potential Breakthrough in Breast Cancer Treatment
@AtossaInc is targeting one of oncology’s toughest challenges—metastatic breast cancer—with its lead asset, (Z)-endoxifen, a next-generation SERM showing promising clinical activity and a strong safety profile. With multiple Phase 2 trials underway and a proprietary oral formulation, Atossa is building a strategic path to address this high-need market.
💡 Why This Matters for Investors:
✅ High-Unmet Need: Focus on metastatic breast cancer, where current treatments fall short.
✅ Accelerated Path: Targeted approach may streamline regulatory approval and speed up market entry.
✅ Strong IP & Cash Position: Debt-free, well-capitalized, and protected by robust intellectual property.
✅ Broad Expansion Potential: Clinical data supports future use in prevention, neoadjuvant, and adjuvant settings.
🎯 With clinical catalysts on the horizon, $ATOS offers investors a compelling opportunity at a major inflection point.
🔗 https://t.co/giFu2sQBHI
$ATOS $PFE $LLY $AZN $KURA $GLPG #ATOS #BiotechInvesting #BreastCancer #OncologyInnovation #ClinicalTrials #SmallCapStocks #PharmaInvesting #InvestSmart
@elonmusk Thank you for looking into these anomalies, such as the “dead pool”! I’m sure you also have a team looking into all the accounts going offshore and mega multiples going to one address. The more you sweep, the more dirt you will uncover.
@atossainc sums up a very successful #SABCS24
$ATOS #breastcancer - Check out all of our announcements from this week's San Antonio Breast Cancer Symposium here https://t.co/Vd9Yf9ldvF
Daré Bioscience Announces Publication in Sexual Medicine of Positive Findings from Demographic, Behavioral and Medication Use Subgroup Analyses in the Phase 2b RESPOND Clinical Study of Sildenafil Cream $DARE https://t.co/lMR5c3g5FK
Wanted to tell you guys about something. I just found out that a bunch of women are trying to start a boycott of a needlepoint store that belongs to a good friend of mine, because they suspect that she doesn't adhere to the woke beliefs.
These women didn't get the memo that the Woke Era is over.
If you are interested in needlepoint, check out my friend's store's website (and if you're in NY, go on in and say "Hi").
https://t.co/D7nU8yrujI
LET'S RECLAIM THE NARRATIVE!!!
If you're a Trump supporter who doesn't hate gay people give this post a retweet!
Let's smash the lie that Republicans hate gay people.
Daré Bioscience Announces Grant to Support Development of a Novel Non-Hormonal Contraceptive Candidate and Expansion of Ovaprene® Pivotal Study Clinical Trial Sites $DARE https://t.co/ljuJOniyr2